Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADC Therapeutics SA

2.85
+0.05001.79%
Post-market: 2.78-0.0700-2.46%16:52 EDT
Volume:323.60K
Turnover:906.76K
Market Cap:282.66M
PE:-1.97
High:2.85
Open:2.83
Low:2.74
Close:2.80
Loading ...

ADC Therapeutics Announces New Inducement Plan Granting Stock Options to New Employee

Reuters
·
02 Jul

ADC Therapeutics files to sell 27.73M common shares for holders

TIPRANKS
·
01 Jul

ADC Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
20 Jun

RBC Adjusts Price Target on ADC Therapeutics Ltd to $5 From $8, Maintains Outperform, Speculative Risk Rating

MT Newswires Live
·
20 Jun

RBC Capital Sticks to Its Buy Rating for ADC Therapeutics (ADCT)

TIPRANKS
·
20 Jun

ADC Therapeutics falls -4.6%

TIPRANKS
·
18 Jun

ADC Therapeutics announces new data from Phase 2 trial of Zynlonta

TIPRANKS
·
16 Jun

ADC Therapeutics SA to Present Updated ZYNLONTA® Trial Data at International Conference on Malignant Lymphoma

Reuters
·
16 Jun

ADC Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
13 Jun

ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site

MT Newswires Live
·
12 Jun

ADC Therapeutics to sell 13M shares at $3.53 in private placement

TIPRANKS
·
12 Jun

ADC Therapeutics Shares up 2.8% Premarket; Co to Reduce Workforce by 30%, Announces $100 Million Private Placement

THOMSON REUTERS
·
12 Jun

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway Into 2028

THOMSON REUTERS
·
12 Jun

ADC Therapeutics Sa - Estimates One-Time Cash Restructuring Charges of $6-$7 Mln

THOMSON REUTERS
·
12 Jun

ADC Therapeutics Sa - to Shut Down UK Facility and Reduce Workforce by 30%

THOMSON REUTERS
·
12 Jun

ADC Therapeutics Sa - Selling 13 Mln Shares at $3.53 Each and 15.7 Mln Warrants at $3.43 Each

THOMSON REUTERS
·
12 Jun

Press Release: ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Dow Jones
·
12 Jun

ADC Therapeutics Announces Promising LOTIS-7 Trial Results for ZYNLONTA® & Glofitamab Combo in r/r DLBCL Patients

Reuters
·
12 Jun

ADC Therapeutics Sa - 25 of 26 Patients Remain in Complete Response as of Data Cut-off

THOMSON REUTERS
·
12 Jun

ADC Therapeutics Sa - Expands Lotis-7 Enrollment to 100 Patients

THOMSON REUTERS
·
12 Jun